Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer

Abstract

Lung cancer remains the leading cause of cancer-related mortality worldwide. Non-small-cell lung cancer (NSCLC) is the most common type and is still incurable for most patients at the advanced stage. Targeted therapy is an effective treatment that has significantly improved survival in NSCLC patients with actionable mutations. However, therapy resistance occurs widely among patients leading to disease progression. In addition, many oncogenic driver mutations in NSCLC still lack targeted agents. New drugs are being developed and tested in clinical trials to overcome these challenges. This review aims to summarize emerging targeted therapy that have been conducted or initiated through first-in-human clinical trials in the past year.

Brain metastases: Comparing clinical radiological differences in patients with lung and breast cancers treated with surgery

“…7 ). 23 , 24 , 25 , 26 In this study, the natural histories of breast and lung cancer patients are consistent with those reported by others. 27 , 28 Still, under clinical, radiological and surgical aspects, there are some interesting differences especially regarding age, clinical debut, timing, extracranial metastases and surgical features.…”

Tiempo al acceso al tratamiento dirigido en cáncer de pulmón de células no pequeñas no escamoso metastásico

“…En la última década, la investigación en cáncer de pulmón se ha centrado en comprender la biología tumoral, desarrollar tratamientos dirigidos y evaluar su aplicación en estadios tempranos. Este enfoque ha resultado especialmente revolucionario gracias al descubrimiento de mutaciones accionables en el CPCNP, generando mejoras sustanciales en la supervivencia de los pacientes afectados por estas mutaciones 6 .…”

Cutting-Edge Therapies for Lung Cancer

“…Molecular alterations such as EGFR mutations, ALK rearrangements, ROS1 rearrangements, RET rearrangements, NTRK fusions, MET mutations, KRAS mutations, BRAF V600E mutations, and HER2 mutations are the contributing factors that underlie the aggressiveness of lung cancer. Therefore, targeted therapies are designed to overcome the consequences of these mutations and primarily achieve great success in the treatment and prognosis of this formidable disease, resulting in an improved survival rate [ 7 ]. Despite the emergence of such therapies, significant challenges remain, as oncogenic driver mutations lack specific targeted agents, and resistance is a recurring issue.…”

“…Clinical investigations have evaluated the effectiveness of additional inhibitors in patients with ROS1-positive NSCLC, including repotrectinib [ 61 ] and taletrectinib [ 62 ]. Both of these inhibitors received FDA approval in 2022 [ 7 ].…”